Aptamer-conjugated PEGylated quantum dots targeting epidermal growth factor receptor variant III for fluorescence imaging of glioma

Int J Nanomedicine. 2017 May 22:12:3899-3911. doi: 10.2147/IJN.S133166. eCollection 2017.

Abstract

The extent of resection is a significant prognostic factor in glioma patients. However, the maximum safe resection level is difficult to determine due to the inherent infiltrative character of tumors. Recently, fluorescence-guided surgery has emerged as a new technique that allows safe resection of glioma. In this study, we constructed a new kind of quantum dot (QD)-labeled aptamer (QD-Apt) nanoprobe by conjugating aptamer 32 (A32) to the QDs surface, which can specially bind to the tumors. A32 is a single-stranded DNA capable of binding to the epidermal growth factor receptor variant III (EGFRvIII) specially distributed on the surface of glioma cells. To detect the expression of EGFRvIII in human brain tissues, 120 specimens, including 110 glioma tissues and 10 normal brain tissues, were examined by immunohistochemistry, and the results showed that the rate of positive expression of EGFRvIII in the glioma tissues was 41.82%, and 0.00% in normal brain tissues. Besides, the physiochemical properties of QD-Apt nanoparticles (NPs) were thoroughly characterized. Biocompatibility of the NPs was evaluated, and the results suggested that the QD-Apt was nontoxic in vivo and vitro. Furthermore, the use of the QD-Apt in labeling glioma cell lines and human brain glioma tissues, and target gliomas in situ was also investigated. We found that not only could QD-Apt specially bind to the U87-EGFRvIII glioma cells but also bind to human glioma tissues in vitro. Fluorescence imaging in vivo with orthotopic glioma model mice bearing U87-EGFRvIII showed that QD-Apt could penetrate the blood-brain barrier and then selectively accumulate in the tumors through binding to EGFRvIII, and consequently, generate a strong fluorescence, which contributed to the margins of gliomas that were visualized clearly, and thus, help the surgeons realize the maximum safe resection of glioma. In addition, QD-Apt can also be applied in preoperative diagnosis and postoperative examination of glioma. Therefore, these achievements facilitate the use of tumor-targeted fluorescence imaging in the diagnosis, surgical resection, and postoperative examination of glioma.

Keywords: EGFRvIII; aptamer; brain glioma; extent of resection; quantum dot; tumor-targeted imaging.

MeSH terms

  • Animals
  • Aptamers, Nucleotide / chemistry*
  • Aptamers, Nucleotide / pharmacokinetics
  • Biotin / chemistry
  • Brain Neoplasms / diagnostic imaging*
  • Cell Line, Tumor
  • DNA, Single-Stranded / chemistry
  • DNA, Single-Stranded / metabolism
  • ErbB Receptors / genetics*
  • ErbB Receptors / metabolism
  • Fluorescence
  • Glioma / diagnostic imaging*
  • Glioma / metabolism
  • Humans
  • Male
  • Mice, Inbred C57BL
  • Molecular Targeted Therapy / methods
  • Nanostructures / chemistry
  • Polyethylene Glycols / chemistry
  • Quantum Dots / chemistry*
  • Quantum Dots / toxicity
  • Tissue Distribution

Substances

  • Aptamers, Nucleotide
  • DNA, Single-Stranded
  • Polyethylene Glycols
  • Biotin
  • EGFR protein, human
  • ErbB Receptors